Figure 3
From: Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
Impact of OX40 and OX40L expression on clinical outcome. The Overall Survival (OS) in AML patients is shown according to OX40L (a) and OX40 (b) expression (4 quartiles identified between minimal and maximal expression) in Kaplan–Meier analysis. OS in patients with OX40high and OX40low expression is shown (Kaplan–Meier analysis) (c). Median OS was reached in OX40high (dotted line) and OX40low (continuous line) patients after 6 and 23.2 months, respectively, and differed significantly (log-rank test). Progression-free survival (PFS) is shown according to OX40 expression in Kaplan–Meier analysis (d). PFS of OX40high (dotted line) and OX40low (continuous line) patients was 4.2 and 63.5 months, respectively, and differed significantly (log-rank test). OS of OX40high (dotted line) and OX40low (continuous line) transplanted patients is shown (Kaplan–Meier analysis) (e). Median OS was reached for OX40high patients after 21.97 months. A multivariate survival analysis (cox regression) including the expression of OX40 (high. vs low), patients’ age (< 60 vs. > = 60 years), FLT3-ITD and the ASCT status of 65 AML patients was performed (f). HR = Hazard ratio, 95% CI = 95% confidence interval.
